08 May Complix to Present Progress on its Pipeline of Cell Penetrating Alphabodies at BioEquity Europe 2019
Hasselt, May 8, 2019 – Complix, a biopharmaceutical company developing Cell Penetrating Alphabodies (CPABs) to target intracellular disease targets, announces that its Chief Executive Officer, Dr Mark Vaeck, will be presenting at the 20th Annual BioEquity Europe Conference in Barcelona, Spain, May 20-21.
In his presentation Dr Vaeck will provide an overview of Complix’ recent achievements in applying its CPAB platform to develop next-generation therapeutics acting on important but intractable intracellular targets.
The presentation will take place on Monday May 20th at 16.50h CET in room Vivaldi 1 of the Crown Plaza Barcelona Fira Center Hotel.
Complix is a biopharmaceutical company developing a pipeline of transformative Cell Penetrating Alphabody (CPAB) based biotherapeutics active against intracellular targets that play a key role in life threatening diseases, including cancer, inflammation and CNS diseases.
These CPABs act with great precision and high affinity on targets that are considered intractable by current drug formats, such as antibodies or small chemicals. Complix is developing a pipeline of CPABs primarily focusing on intracellular oncogenic targets that play a key role in cancer development and progression. The Company is currently running multiple CPAB programs based on selection from a diverse collection of undruggable targets, two of which are being developed in a $280 million partnership with Merck & Co.
Complix believes that, thanks to their unique capacity to address a broad universe of intractable targets, CPABs represent an entirely novel class of therapeutics that have the potential to significantly improve treatment outcomes for patients.
Complix has established a strong intellectual property position protecting the Alphabody platform and its emerging product portfolio through the filing of multiple broad patent applications. Since its foundation in 2008 Complix has raised more than €27 million through several rounds of equity financing.
Dr. Mark Vaeck
+32 9 261 69 40